Companies Dominating the Pyomyositis Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- GlaxoSmithKline (GSK)
- Novartis International AG
- Sanofi S.A.
- Johnson & Johnson
- Roche Holding AG
- AstraZeneca PLC
- Gilead Sciences, Inc.
- Teva Pharmaceutical Industries Ltd.
Browse Key Market Insights with Data Illustration:
In the News
- Merck acquired VXRT Inc., a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, for USD 3.2 billion. The acquisition strengthened Merck's vaccine pipeline and added new vaccine candidates for COVID-19 and other infectious diseases.
- Merck acquired Peloton Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapies for the treatment of cancer, for USD 1.1 billion. The acquisition added several new cancer therapy candidates to Merck's pipeline, including PT-101, a small molecule inhibitor of DDR1, and PT-102, a small molecule inhibitor of MTAP.
